{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-006028","form_type":"8-K","ticker":"MGX","cik":"0001785279","company_name":"Metagenomi Therapeutics, Inc.","filed_at":"2025-01-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.850335+00:00","generated_at":"2026-05-28T00:11:18.046600+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Metagenomi adds Eric Bjerkholt to board; board size increases to six","bullets":["Eric Bjerkholt appointed as Class II director effective Jan 27, 2025; board expands from five to six.","Bjerkholt is CFO of Mirum Pharmaceuticals; previously CFO at Chinook, Aimmune, Sunesis.","He will serve on Audit and Compensation Committees; receives initial option grant of 42,000 shares vesting over 3 years.","Company updated investor deck for J.P. Morgan Healthcare Conference; no specific pipeline details disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-006028","json":"https://secwatch.observer/filing/0000950170-25-006028.json","markdown":"https://secwatch.observer/filing/0000950170-25-006028.md","text":"https://secwatch.observer/filing/0000950170-25-006028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785279/000095017025006028/0000950170-25-006028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785279/000095017025006028/mgx-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T00:11:18.046600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1bc2d47fbb","claim":"Eric Bjerkholt was appointed as Class II Director at Metagenomi Therapeutics, Inc..","evidence_excerpt":"appointed Eric Bjerkholt to serve as a director of the Board, each effective as of January 27, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017025006028/0000950170-25-006028-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}